Compare SMCI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMCI | RVMD |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 19.2B |
| IPO Year | 2006 | N/A |
| Metric | SMCI | RVMD |
|---|---|---|
| Price | $25.24 | $96.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 17 |
| Target Price | $35.44 | ★ $120.47 |
| AVG Volume (30 Days) | ★ 39.0M | 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $2,484,929,000.00 | N/A |
| Revenue This Year | $92.37 | N/A |
| Revenue Next Year | $21.47 | $411.49 |
| P/E Ratio | $26.95 | ★ N/A |
| Revenue Growth | ★ 11.68 | N/A |
| 52 Week Low | $19.48 | $34.00 |
| 52 Week High | $62.36 | $124.49 |
| Indicator | SMCI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 48.24 |
| Support Level | $19.48 | $93.39 |
| Resistance Level | $33.17 | $101.00 |
| Average True Range (ATR) | 1.46 | 3.12 |
| MACD | 0.33 | 0.21 |
| Stochastic Oscillator | 94.99 | 51.05 |
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.